19 Comments

Fascinating. I had no idea. My background is in biotech (sales and marketing side) and you’re right, that path to Phase 1 clinical trials is loaded with landmines, roadblocks, and obstacles that prevents countless projects from ever getting off the ground. Number of compounds out there with potential are countless but the way the system is set up now, risk is avoided in exchange for projects that are considered more likely to succeed but not necessarily a significant advancement in science. How many patients will never get treatment from a game-changing drug because the funding for it was never there to bring it to fruition. Instead, the safe bet for VC and pharma is to just tweak an existing proven compound, file with regulatory, and extend a patent on a drug that doesn’t really move the needle vs what could have been with an entirely different class.

Expand full comment

This is pretty amazing. Future app I can think of.

Having a rare genetic disorder. However, outcomes are minor and only 1-2M people have it worldwide. So no funding, few specialists, and no cure.

This would allow you to create an "Disorder" Dao. And get funding together from thousands in same situation.

Expand full comment
founding

Thanks for the writeup.

1) Peer review is a pain in the ass from a reviewer perspective. To do it right, I need to spend a solid 8hrs on a manuscript to dig through the details, understand the nuances of the experimental setup and the analytical tools used. There is no compensation for this, and importantly, nobody has time to do this. I suspect most articles probably get 1-2hrs tops per reviewer, so much shit gets published. You really need dedicated reviewers, but then, they need to know the intricacies of that topic so...

2) 100% finding the right people to join a DAO is going to be hard. To get someone who understands design to value, ie the full circle of product fit, legal, biological relevancy, and manufacturing is hard. e.g. an unamed top 3 medtech company in US invented automatic suturing device, full FDA approval, saved time, shilled by all the KOLs at conferences, but no surgeon bought it cuz turns out, surgeons love to sow shit up at the end lol.

3) Pharma has set up innovation centers around the globe to incubate startups, seems to save them money on internal R&D. Would be interesting to see a DAO get integrated into those networks to help fund the more risky early ventures with interested companies already at the table.

Excited to see how this turns out.

Expand full comment

Very interesting. Do you think it’s possible/useful for DAO SPVs and the R&D activities they enable (for those facing the back end of the drug discovery process) to be domiciled in emerging jurisdictions that provide freedom in regard to medical and legal entity regulations?

Expand full comment

This is all great, but when it comes time to pay people, pay for lab time, pay for trials, dollars are needed $$$. Will these DAOs deal in dollars or in some new token? Same issue that I see with much of crypto. You can't buy food or property or lab equipment with XYZ coin.

Expand full comment
founding

Super interesting! Do you think this has legs to bleed over into dx/tools space? I know you mentioned genomics as something already in motion

Expand full comment

Asking for a friend. Manager (sales) at tech company $350k been offered a Engagement manager equivalent at MBB for $350k (possibly $420 with year end bonus) with the carrot of associate partner within 2yrs. Already have wifi biz 200k/yr profits setup. Stick with tech or go MBB?

Expand full comment

Thanks bowtied bull for all the information, definitely life changing stuff. I haven’t figured out how to carve my niche into Wi-Fi money but I’ve turned the wfh hustle to the max.

Expand full comment